Compare organizations

McKesson Europe fully supports the European Commission’s (EC) evaluation of the General Pharmaceutical Legislation. We strongly believe that the EU’s General Pharmaceutical Legislation is overdue a comprehensive review. The EC needs to utilize this opportunity and make General Pharmaceutical Legislation more effective for European patients.

EFPIA supports an agile regulatory framework and a strong incentives’ system that embrace and encourage advances in science, technology & medicines. This evaluation is an opportunity to implement learnings from COVID-19 and ensure a competitive, world-class regulatory system in Europe supporting a globally competitive research-based industry at a critical time.

EFPIA supports the objectives of enhancing the availability and accessibility of medicines, while fostering a competitive innovation environment in Europe. We welcome the proposal to future-proof the EU regulatory framework, maximising the use of expedited pathways, optimising regulatory decision-making processes, and reducing unnecessary administrative burdens.

EFPIA supports the objectives of enhancing the availability and accessibility of medicines, while fostering a competitive innovation environment in Europe. We welcome the proposal to future-proof the EU regulatory framework, maximising the use of expedited pathways, optimising regulatory decision-making processes, and reducing unnecessary administrative burdens.

McKesson Europe fully supports the European Commission’s initiative “Digital health data and services – the European health data space”. We would like to use this opportunity to contribute to the ongoing roadmap consultation and flag areas where EU policy action can further be improved.

EFPIA welcomes the proposal to create sectoral and horizontal legislative frameworks to unlock the value of data, support the use, re-use and exchange of health data at the EU level and ensure coherence between the operation of the different legislations contributing to the functioning of the Data Space.

The legislative proposal on a European Health Data Space (EHDS) and respective horizontal proposals provide an unprecedented opportunity to shape the future health data and digital ecosystem. Digital transformation has the potential to increase the innovation and productivity of the EU economy and ensure that Europe remains an innovator and world leader in the development and manufacture of medicines, supporting…

McKesson Europe fully supports EMA’s extended role in addressing public health emergencies including their new role in monitoring medicine shortages. We also support EMA’s definition of medicine shortages as defined in Art. 2 / (d) of the regulation ( “shortage” means that supply of a medicinal product for human use or a medical device does not meet demand for that medicinal product or medical device”).

EFPIA fully supports the EU’s goal to enhance its health emergency preparedness and response capacity by, among others, extending the mandate of the EMA. The current crisis has shown the importance of close dialogue between EU authorities and the industry, to address medicines’ shortages.